No CYP-affinity. No conceivable effects on PXR activation. However, side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Cetuximab is a recombinant chimeric (human-murine) monoclonal antibody.

Cetuximab is an antineoplastic agent used to treat colorectal cancer with metastases and cancers in the head and neck. It is administered as an intravenous infusion. Common adverse reactions of cetuximab that can be confused with an acute porphyric attack are nausea, vomiting, abdominal pain, diarrhea and dyspnoea. Side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Cetuximab is metabolized in the same way as as endogenous IgG. Non-CYP metabolism.